FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:59-60 January 4, 2001 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Goldberg, A. B. PubMed Citation

The article by Goldberg et al. in this issue of the Journal reviews the evidence supporting the use of misoprostol in women at various stages of pregnancy.¹ The authors identified more than 200 studies involving more than 16,000 women who received misoprostol and conclude that "misoprostol is one of the most important medications in obstetrical practice."¹ The product-information enclosure approved by the Food and Drug Administration (FDA) states that misoprostol is indicated for the prevention of gastric ulcers caused by nonsteroidal antiinflammatory drugs in patients who are at high risk for these ulcers.² The contraindications include pregnancy, because of misoprostol's . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Gebhardt, D O E (2001). Misoprostol in a topsyturvy world. J. Med. Ethics 27: 205-205 [Full Text]  
• Friedman, M. A. (2001). Manufacturer's Warning Regarding Unapproved Uses of Misoprostol. NEJM 344: 61-61 [Full Text]